FOCUS-CCTRN 2012

NCT00824005

1 Treatments

Studied treatment  autologous bone-marrow-cell therapy

Control treatment

Concomittant treatments  -

cell type  -

Cell injection procedure  -

2 Patients

Patients  patients with chronic ischemic heart failure

Inclusion criteria  patients with coronary artery disease, LVEF of <45%, limiting angina and/or congestive heart failure, a perfusion defect by SPECT, and no revascularization options while receiving guideline-based medical therapy

Exclusion criteria  -

3 Methods

Blinding  -

Design  -

Centers  -

Geographical area  -

Sizes  92/0

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>acute heart failure</td>
<td>-/92</td>
<td>-/0</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>ventricular tachycardia</td>
<td>-/92</td>
<td>-/0</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>NYHA deterioration</td>
<td>-/92</td>
<td>-/0</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiac event</td>
<td>-/92</td>
<td>-/0</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all-cause mortality</td>
<td>-/92</td>
<td>-/0</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References